Although Qian and colleagues [13] mainly focused their work on neuronal reprogramming of astrocytes via AAV Ptb silencing, they also tested astrocyte transdifferentiation using a specific ASO as a feasible, single-step approach to treat Parkinson’s disease and likely other neurodegenerative conditions. This evidence concerns the gene PTBP2 and Parkinson disease.